Trial Profile
Phase 2 study of ACER-003 for systemic scleroderma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2016
Price :
$35
*
At a glance
- Drugs Acetylcysteine (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- 20 May 2016 According to Acer Therapeutics website, the company plans to initiate the trial in the second quarter of 2016 and complete in approximately first quarter of 2019.
- 20 May 2016 New trial record